Santa Rosa, California 95403

  • Cancer


Mental health issues in post-treatment adult cancer survivors are associated with multiple adverse outcomes and may represent a cancer health disparity for rural survivors. The purpose of this study is to test a stepped-care approach tailored to symptom severity based on recent American Society of Clinical Oncology guidelines for reducing emotional distress (anxiety and/or depressive symptoms) and improving secondary outcomes (sleep disturbance, fatigue, fear of recurrence, quality of life) in rural, post-treatment cancer survivors in community oncology settings and to examine intervention costs. The resultant intervention will have great potential for widespread dissemination since it will be manualized, delivered by telephone, and comprised of modules to allow customized treatments for individuals with different cancer types.


Inclusion Criteria: - Age ≥18 years - Score ≥10 on the GAD-7 and/or a score ≥8 on the PHQ-9, indicating clinically significant anxiety or depressive symptoms, respectively. - Past history of treated Stage I, II, or III (newly diagnosed or recurrent) breast, colorectal, prostate, gynecologic (to include uterine and cervical) cancers and non-Hodgkin's lymphoma. - 6-60 months post-treatment (surgery, chemotherapy, and/or radiation therapy) for cancer. Time frame applies to most recent completion of treatment if participant had a cancer recurrence. It is acceptable to be on maintenance or hormonal therapies. - Participant resides in California, Georgia, Illinois, Kansas, Michigan, Minnesota, Missouri, New Mexico, North Carolina, North Dakota, South Carolina, Virginia, Tennessee, or Wisconsin - Study-trained therapist in the state where the participant resides. - Must be able to speak and understand English. - Must have access to a telephone Exclusion Criteria: - Current psychotherapy [regular appointment(s) with a psychologist, counselor, or therapist within the last 30 days prior to randomization]. - Self-reported active alcohol or substance abuse within the last 30 days. - Past history of prostate cancer or non-Hodgkin's lymphoma with only active surveillance (i.e., no surgery, chemotherapy, or radiation therapy). - Diagnosis of a second malignancy (except for non-melanoma skin cancers) after a previous diagnosis of breast, colorectal, gynecologic cancers and non-Hodgkin's lymphoma - Progressive cancer (must be considered no evidence of disease or stable) - Self -reported history of a diagnosis of dementia from a healthcare provider. - Self -reported psychotic symptoms in the last 30 days prior to randomization - Active suicidal ideation (currently reported suicidal plan and intent). - Any change in psychotropic medications within the last 30 days. - Hearing loss that would preclude participating in telephone sessions (determined by brief hearing assessment administered by research staff) - Failure/inability/unwillingness to provide names and contact information for two family members or friends to serve as emergency contacts during the course of the study.



Primary Contact:

Principal Investigator
Suzanne Danhauer, PhD
Wake Forest Baptist Medical Center

Backup Contact:


Location Contact:

Santa Rosa, California 95403
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 24, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.